Matthew Sykes
Stock Analyst at Goldman Sachs
(3.31)
# 501
Out of 5,182 analysts
197
Total ratings
55.47%
Success rate
11.37%
Average return
Main Sectors:
Stocks Rated by Matthew Sykes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FTRE Fortrea Holdings | Maintains: Neutral | $7 → $5 | $10.37 | -51.76% | 4 | May 14, 2025 | |
| CTKB Cytek Biosciences | Maintains: Sell | $3.5 → $3 | $4.61 | -34.92% | 14 | May 12, 2025 | |
| TXG 10x Genomics | Maintains: Sell | $7.5 → $6.5 | $26.08 | -75.08% | 7 | May 12, 2025 | |
| BRKR Bruker | Maintains: Neutral | $50 → $45 | $40.70 | +10.57% | 5 | May 8, 2025 | |
| MYGN Myriad Genetics | Maintains: Buy | $14 → $8 | $5.08 | +57.48% | 12 | May 7, 2025 | |
| TWST Twist Bioscience | Maintains: Buy | $55 → $48 | $59.81 | -19.75% | 10 | May 6, 2025 | |
| SHC Sotera Health Company | Upgrades: Buy | $14 → $17 | $16.30 | +4.29% | 1 | May 5, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $180 → $160 | $119.68 | +33.69% | 4 | May 2, 2025 | |
| NEO NeoGenomics | Maintains: Buy | $15 → $10 | $8.35 | +19.76% | 8 | Apr 30, 2025 | |
| RVTY Revvity | Maintains: Buy | $140 → $125 | $93.96 | +33.04% | 2 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $23 → $14 | $8.52 | +64.32% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $240 | $194.75 | +23.23% | 5 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $26 | $21.42 | +21.38% | 10 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $190 → $170 | $183.88 | -7.55% | 4 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $56 | $90.36 | -38.03% | 13 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $80 | $65.96 | +21.29% | 11 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.75 → $1.5 | $1.69 | -11.24% | 5 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $160 → $190 | $208.40 | -8.83% | 13 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $2.25 → $1.75 | $3.03 | -42.24% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $7 → $4.25 | $3.39 | +25.37% | 10 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $38 → $37 | $33.80 | +9.47% | 5 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $280 → $250 | $176.46 | +41.68% | 2 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $24 | $3.50 | +585.71% | 13 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,150 → $1,300 | $1,340.58 | -3.03% | 7 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $12 | $8.03 | +49.44% | 6 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $640 | $526.60 | +21.53% | 6 | Apr 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $128 → $145 | $121.87 | +18.98% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $41.24 | - | 5 | Dec 7, 2023 |
Fortrea Holdings
May 14, 2025
Maintains: Neutral
Price Target: $7 → $5
Current: $10.37
Upside: -51.76%
Cytek Biosciences
May 12, 2025
Maintains: Sell
Price Target: $3.5 → $3
Current: $4.61
Upside: -34.92%
10x Genomics
May 12, 2025
Maintains: Sell
Price Target: $7.5 → $6.5
Current: $26.08
Upside: -75.08%
Bruker
May 8, 2025
Maintains: Neutral
Price Target: $50 → $45
Current: $40.70
Upside: +10.57%
Myriad Genetics
May 7, 2025
Maintains: Buy
Price Target: $14 → $8
Current: $5.08
Upside: +57.48%
Twist Bioscience
May 6, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $59.81
Upside: -19.75%
Sotera Health Company
May 5, 2025
Upgrades: Buy
Price Target: $14 → $17
Current: $16.30
Upside: +4.29%
ICON Public Limited Company
May 2, 2025
Maintains: Neutral
Price Target: $180 → $160
Current: $119.68
Upside: +33.69%
NeoGenomics
Apr 30, 2025
Maintains: Buy
Price Target: $15 → $10
Current: $8.35
Upside: +19.76%
Revvity
Apr 29, 2025
Maintains: Buy
Price Target: $140 → $125
Current: $93.96
Upside: +33.04%
Apr 29, 2025
Downgrades: Neutral
Price Target: $23 → $14
Current: $8.52
Upside: +64.32%
Apr 23, 2025
Maintains: Buy
Price Target: $260 → $240
Current: $194.75
Upside: +23.23%
Apr 17, 2025
Maintains: Buy
Price Target: $34 → $26
Current: $21.42
Upside: +21.38%
Mar 21, 2025
Downgrades: Neutral
Price Target: $190 → $170
Current: $183.88
Upside: -7.55%
Feb 21, 2025
Maintains: Buy
Price Target: $49 → $56
Current: $90.36
Upside: -38.03%
Feb 19, 2025
Maintains: Neutral
Price Target: $70 → $80
Current: $65.96
Upside: +21.29%
Feb 18, 2025
Maintains: Neutral
Price Target: $1.75 → $1.5
Current: $1.69
Upside: -11.24%
Jan 28, 2025
Maintains: Buy
Price Target: $160 → $190
Current: $208.40
Upside: -8.83%
Dec 5, 2024
Downgrades: Sell
Price Target: $2.25 → $1.75
Current: $3.03
Upside: -42.24%
Dec 5, 2024
Downgrades: Sell
Price Target: $7 → $4.25
Current: $3.39
Upside: +25.37%
Dec 5, 2024
Downgrades: Neutral
Price Target: $38 → $37
Current: $33.80
Upside: +9.47%
Nov 1, 2024
Maintains: Buy
Price Target: $280 → $250
Current: $176.46
Upside: +41.68%
Jul 9, 2024
Maintains: Buy
Price Target: $35 → $24
Current: $3.50
Upside: +585.71%
Jul 9, 2024
Maintains: Neutral
Price Target: $1,150 → $1,300
Current: $1,340.58
Upside: -3.03%
Jul 9, 2024
Maintains: Sell
Price Target: $32 → $12
Current: $8.03
Upside: +49.44%
Apr 10, 2024
Maintains: Buy
Price Target: $550 → $640
Current: $526.60
Upside: +21.53%
Dec 7, 2023
Maintains: Buy
Price Target: $128 → $145
Current: $121.87
Upside: +18.98%
Dec 7, 2023
Upgrades: Buy
Price Target: n/a
Current: $41.24
Upside: -